ASX Announcement
16 July 2026

Q4 FY26 QUARTERLY ACTIVITIES REPORT & APPENDIX 4C

FY26 core testing revenue up 92% and core testing volume up 78% vs PCP.

Microba Life Sciences Limited (ASX: MAP) ("Microba" or the "Company"), a company at the forefront of microbiome diagnostics and therapeutics, is pleased to provide a summary of its activities for the quarter ended 30 June 2026, and for the financial year ended 30 June 2026.

Key Highlights

- **Record core testing growth**
  - Q4 core test volumes up 54% vs PCP. Annualised run rate 25,000+
  - FY26 core testing volume of 22,418 tests, up 78% year-on-year from 12,629 in FY25.
- **Key enterprise accounts growing in Australia**
  - 43 key accounts now signed since November 2025, as at end of June those accounts sold 5,600+ tests, up 87% quarter-on-quarter.
- **On track to launch new GI Navigator testing product in September**
  - The first 35 GI Navigator sales already achieved as part of an early access program across Australia and the United Kingdom with key opinion leading clinicians.
- **Cost reduction programme on track**
  - The streamlining of operations to a structurally lower cost base is well progressed, with targeted total annual cash costs expected to reduce by over $7m per year once fully implemented with full benefit expected to be realised in H1 FY27.
- **Therapeutic Partnering active**
  - Microba attended the 2026 BIO International Convention in San Diego, and hosted partnering meetings supported by the Company's Boston-based advisors, as a precursor to a formal partnering campaign planned to commence from July 2026.



Financial Performance

- **Q4 FY26 cash receipts of $3.95m, broadly flat QoQ and vs PCP**
- **Q4 FY26 total revenue of $4.07m, up 21% QoQ and down 2% vs PCP**
- **FY26 total revenue of $14.78m, down 6% YoY, reflecting the completed phase out of strategically discontinued legacy product revenues and a focus on Microba's core testing, and Invivo supplement products.**
  - Continuing product revenue grew 53% from $8.3m to $12.73m, not including a growing core testing deferred revenue balance of $1.79m at 30 June 2026, up 66% vs PCP and up 15% QoQ
  - Discontinuing product revenue reduced 72% from $7.36m to $2.05m.
- $5.0m placement completed (plus an SPP of up to $1.0m) at $0.05 per share to fund the path to cashflow break-even.
- The Quarterly Investor Webinar will be held 12:00pm (midday) AEST on Thursday, 16 July 2026. You can register and access the live webinar and subsequent recording via this link: https://ir.microba.com/webinars/yOO1wy-q4-fy26-quarterly-investor-webinar

Commenting on the quarter, Microba's CEO, Dr Luke Reid, said:

"FY26 was a year of disciplined execution and strong growth in our core testing business. Core testing revenue grew 92% for the financial year, and we delivered approximately 22,400 core tests, up 78% versus FY25. Q4 capped the year with a record quarter: core testing revenue of $2.53 million, up 45% versus the prior corresponding period, and core test volume up 54% versus the prior corresponding period. Our rolling-quarter annualised run rate now exceeds 25,000 tests.

In Australia, Microbiome Explorer delivered another record quarter, with 5,311 tests sold, up 54% versus the prior corresponding period. Our strategy focused on enterprise-style contracts with healthcare clinics continued to deliver, with the signed key-account base underwriting a substantial share of the growth ahead as those accounts mature.

In the United Kingdom, adoption of Microbiome Explorer continued to build, with 825 tests sold in the quarter, up 92% on the prior corresponding period.

FY26 revenue reflects a deliberate transition of our product portfolio toward growth and scalability. As we completed the planned phase-out of our legacy products, continuing product revenue grew 53% to $12.73 million, while discontinued legacy revenue reduced 72% to $2.05 million. The close to FY26 presents a new revenue base and a clean picture of the new Microba moving into FY27: a focused core testing business with 12 consecutive quarters of growth, alongside a focused portfolio of nutritional supplements delivering new growth.

For our therapeutics business, we attended the 2026 BIO International Convention in San Diego, and hosted partnering meetings supported by our Boston-based advisors, as a precursor to a formal partnering campaign planned to commence from July 2026. A manuscript reporting results from the Phase 1 trial of our lead asset MAP-315 in ulcerative colitis has been provisionally accepted for publication in Nature Communications, titled "A human microbiome-derived therapeutic for ulcerative colitis promotes mucosal healing and immune homeostasis: a randomised phase I trial". This follows the series of positive sector clinical trial readouts through FY26 that continue to strengthen the investment case for live biotherapeutic drugs, supporting the partnering and advancement of Microba's therapeutic assets.

Looking ahead, we remain on track to launch a new category-defining testing product, GI Navigator, in September 2026, with the first 35 GI Navigator sales already achieved as part of an early access program across Australia and the United Kingdom with key opinion-leading clinicians. This new product represents the next meaningful step in the clinical application of complete microbiome and gut testing and is designed to open up our serviceable addressable market to more medical doctors, a significant next segment of the healthcare practitioner market for our tests. At the same time, we have rapidly completed the streamlining of the business to a structurally lower cost base on plan and without impact to our core growth engine, drawing on our existing product, infrastructure and AI-efficiency investments.

With a category-defining product on track for launch, our therapeutics partnering process active, costs reducing and margins expanding - we are focused on delivering the whole company to cashflow break-even."

KEY HIGHLIGHTS

Growing key enterprise accounts in Australia

In Australia, adoption has now moved beyond innovators into early adopters, increasingly characterised by enterprise-style contracts with healthcare clinics. These accounts when signed and activated, represent meaningful recurring volume potential.

At the end of June, there are now over 175 key account targets in the pipeline in Australia, with an estimated ordering potential of over 80,000 tests per annum.

Since we commenced targeting these key accounts in November 2025, we have already signed 43 accounts and sold 5,606 tests, up 87% QoQ. These accounts represent an ordering potential of over 24,000 tests per annum.

These signed accounts continue to grow strongly, underwriting a substantial share of the growth ahead as they mature, and demonstrating the significant growth opportunity from this enterprise channel.



Upcoming new GI Navigator testing product launch

On track to launch GI Navigator, a new category-defining testing product, in September 2026. This product is the culmination of several years of leadership at the forefront of this new diagnostic category. It represents a meaningful leap in the clinical application of complete microbiome and gut testing and is expected to open up our serviceable addressable market to more medical doctors, a significant next segment of the healthcare practitioner market for our tests.

GI Navigator is live now with a closed-group early access cohort of opinion-leading practitioners across AU and UK, with the first 35 sales achieved: multiple parts of the product are already delivering clinical value and receiving positive feedback, the new product is powered by Microba's proprietary one-of-a-kind Clinical Logic Engine.

DIAGNOSTICS

Microba Microbiome Explorer™ Gastrointestinal Disorder Test

Microbiome Explorer delivered another record quarter in Australia, supported by continued signing and maturing of key clinic accounts, focused clinician field engagement, and improved lifecycle marketing. The Australian ordering clinician base reached 901, and orders per clinician grew 34% versus PCP, reflecting maturing key accounts, deepening clinician engagement and the growing productivity of the account base.

	Australia		
	Q4 FY26	**vs Q4 FY25 (PCP)**	**vs Q3 FY26 (QoQ)**
Tests Sold	5,311	3,451, up 54%	4,791, up 11%
Ordering Clinicians	901	785, up 15%	824, up 9%

In the United Kingdom, Microbiome Explorer delivered another record quarter, with 825 tests sold, up 92% versus PCP. The active ordering clinician base reached 313 at quarter end, up 85% versus PCP, as the team focused on clinician field engagement, top-of-funnel qualification, conversion, education and activation of new accounts.

	United Kingdom		
	Q4 FY26	**vs Q4 FY25 (PCP)**	**vs Q3 FY26 (QoQ)**
Microbiome Explorer Tests Sold	825	429, up 92%	816, up 1%
Ordering Clinicians	313	169, up 85%	268, up 17%

MetaPanel™ Gastrointestinal Pathogen Test

MetaPanel test sales of 225 grew 11% QoQ, with ordering clinicians up 8% QoQ, with organic ordering among gastroenterology specialists and key opinion leaders. Focus remains on nurturing key opinion leaders in readiness for future expanded commercialisation and market development for this test.

	Australia		
	Q4 FY26	**vs Q4 FY25 (PCP)**	**vs Q3 FY26 (QoQ)**
Tests Sold	225	264, down 15%	202, up 11%
Ordering Clinicians	141	186, down 24%	130, up 8%

SUPPLEMENTS

Invivo Nutritional Supplements

Invivo own-brand supplement revenue was $0.75m in Q4 FY26, up 11% vs PCP and up 11% QoQ, continuing the momentum in our higher-margin own-brand range. Growth was led by Invivo's leading PHGG prebiotic fibre supplement, whose unit sales more than doubled to 43,000 units in FY26, up 114% on FY25.

The Invivo subscription offering launched in late 2025, grew 230% over the six months to 30 June 2026 to more than 1,000 subscribers, establishing a growing base of recurring own-brand revenue. Revenue from third-party distributed Designs For Health (DFH) supplements continued to reduce, to $0.12m, down 75% vs PCP, as part of the planned managed transition to focus on Invivo's wholly owned higher-margin products.

	Q4 FY26	**vs Q4 FY25 (PCP)**	**vs Q3 FY26 (QoQ)**
Invivo Supplements	$0.75m	$0.68m, up 11%	$0.68m, up 11%
Distributed Supplements (DFH)	$0.12m	$0.46m, down 75%	$0.24m, down 52%

THERAPEUTICS

Microba maintains its competitive advantage in human data-driven discovery from the human microbiome and holds field-leading live biotherapeutic IP assets with deep preclinical and early clinical validation, including MAP-315, which is near Phase 2 ready. All further internal R&D investment remains paused, as previously guided.

Prospective partners have for years been awaiting definitive Phase 1b/2a efficacy data that will validate the live biotherapeutic modality in a major chronic disease setting. Between November 2025 and February 2026, those validating results have been substantially delivered:

- Siolta - Phase 1b/2 Allergic Disease asset read out – 17 Nov 2025 - met their end points.
- Maat Pharma – Phase 3 GvHD asset – 8 Dec 2025 – positive final pivotal results. Regulatory review by the European Medicines Agency for Market Approval ongoing.
- Enterobiotix – Phase 2a IBS asset read out - 8 Jan 2026 – met their end points
- Microbiotica – Phase 1b IBD asset read out – 11 Feb 2026 – met their end points
- Microbiotica – Phase 1b Oncology asset read out – 18 May 2026 - met their end points
- Seres Therapeutics – Open-label Trial Oncology read out – 8 Jul 2026 – positive early data

Aligned to this series of positive sector clinical trial readouts, Microba attended the 2026 BIO International Convention in San Diego, and hosted partnering meetings supported by the Company's Boston-based advisors, as a precursor to a formal partnering campaign planned to commence from July 2026.

Additionally, during the quarter a manuscript reporting results from the Phase 1 trial of the Company's lead asset MAP-315 in ulcerative colitis was provisionally accepted for publication in Nature Communications, titled “A human microbiome-derived therapeutic for ulcerative colitis promotes mucosal healing and immune homeostasis: a randomised phase I trial”.

These readouts and the associated evidence base strengthen the investment case for live biotherapeutic drugs and are expected to support Microba’s active partnering process.

FINANCIALS

Core testing revenue achieved a new record quarter of $2.53 million for Q4 FY26, up 45% versus PCP and up 19% QoQ. Q4 FY26 total revenue was $4.07 million, up 21% QoQ and down 2% versus PCP, reflecting the legacy tests and services revenue that was present in FY25. For the full financial year, FY26 total revenue was $14.78 million, down 6% versus FY25, while core testing revenue grew strongly year-on-year as the strategic transition to a focused core testing business was completed.

Full-year core testing volume reached 22,418 tests, up 78% on the 12,629 tests sold in FY25. While modestly below the 24,000+ tests indicated through the year, the difference reflects the timing of the volume ramp, the business exited FY26 at an annualised run-rate above 25,000 tests, and enters FY27 with strong momentum and a maturing enterprise-clinic account base.

Microba's own-brand Invivo supplement business continued to deliver growth in the quarter, with Invivo revenue of $0.75 million, up 11% versus PCP and up 11% QoQ. Reported total supplement revenue declined versus PCP, reflecting the planned phase out of lower-margin distributed supplement products, with distributed (DFH) revenue of $0.12 million, down 75% versus PCP. The strategic transition to higher-margin own-brand product is expected to support improving supplement gross margins in subsequent periods.

Deferred Revenue

Reflecting Australian Accounting Standards and the Company's aligned revenue recognition policy, testing revenue is recognised at the point a final Microbiome Explorer or MetaPanel report is delivered to the customer, rather than at the point a kit is ordered and paid for.

Microbiome Explorer deferred revenue was $1.79 million at 30 June 2026, up 66% on $1.08 million at 30 June 2025 and up 15% QoQ. The increase reflects the growing volume of kits sold and committed by customers ahead of report delivery, and provides visibility over core testing revenue expected to be recognised through FY27.

Deferred Revenue	30 Jun 2026	31 Mar 2026	30 Jun 2025
Microbiome Explorer	$1,792,095	$1,552,446	$1,078,010

Cash Flow and Cost Discipline

Cash receipts for the quarter totalled $3.95 million, broadly flat against both QoQ and PCP. The stable result reflects the completion of the Company's transition to a focused core testing business, with growth in core testing and own-brand supplement receipts offsetting the strategic roll-off of discontinued legacy products.

Net cash used in operating activities for the quarter was $3.43 million, down 2% QoQ and down 38% on the $5.56 million outflow in Q4 FY25. The reduction reflects a structurally lower cost base achieved through the year, with staff cash costs down approximately $0.9 million, administration and corporate costs down approximately $0.7 million, and product manufacturing and operating costs down approximately $0.7 million versus the same period last year.

Streamlining to a structurally lower cost base

During the quarter the Company substantially progressed a streamlining of operations to reduce its ongoing cash operating cost run-rate by approximately $7 million per annum. The reductions are concentrated in functions where major product build-phase investment is now complete, and in shared functions benefiting from AI-supported efficiency across customer support and back-office functions including finance, marketing and people & culture. They do not reduce the core growth engine or front-line sales capacity.

The streamlining reflects Microba's transition from a build phase to a scale phase. With the multi-year investment in the Company's testing platform, laboratory infrastructure and core product now substantially complete, and operating processes increasingly automated, Microba is able to run a materially lower fixed cost base while retaining the engineering, bioinformatics and commercial capability required to deliver its growth plan. The benefit of the lower cost base will be realised progressively through H1 FY27.

One off costs associated with the restructuring, combined with costs of the corporate transaction that did not proceed and capital raising activities totalled $0.7 million in the quarter.

Combined with the $5.0 million placement announced during the quarter and continued revenue and margin growth on a largely fixed cost base, the lower cost base supports the Company's path toward whole company cashflow break-even.

Capital Position

As at 30 June 2026, Microba held $7.95m in cash and equivalents.

On 12 June 2026 the Company announced a capital raising of up to $6.0 million (before costs), comprising a $5.0 million placement at $0.05 per share and a share purchase plan (SPP) to raise up to a further $1.0 million on the same terms. Strategic partner and shareholder Sonic Healthcare Limited (ASX: SHL) subscribed for $1.5 million.

The SPP remains open to eligible shareholders and closes on 22 July 2026.

Tranche 1 (approximately $4.57 million) settled on 17 June 2026 with funds received during the quarter. Tranche 2 (approximately $0.43 million), the SPP, and one free attaching option per new share (exercisable at $0.0625, expiring three years from issue) are subject to shareholder approval at the General Meeting on 24 July 2026, and would raise up to a further $1.43 million, with Tranche 2 settlement anticipated on 28 July 2026. Full details are set out in the Company's ASX announcements.

The Company continues to hold its $2.0 million R&D Tax Incentive loan facility with Radium Capital, providing working capital ahead of receipt of the FY26 R&D Tax Incentive (expected in H1 FY27).

In accordance with Listing Rule 4.7C, payments made during the quarter to related parties and their associates included in item 6.1 of Appendix 4C totalled $113,879 and comprised director fees.

Commenting on the quarter, Microba's CFO, James Heath, said:

"FY26 reinforces the positive trajectory of Microba, with Microbiome Explorer now contributing the majority of group revenue, our United Kingdom business delivering strong year-on-year unit growth, and our cost streamlining programme well progressed as we move to a structurally lower cost base. Our focus in FY27 is realising the benefit of our prior investments in product and infrastructure, growing our core testing business, launching our market leading new product GI Navigator, expanding margins and reducing the cost base to deliver our path to whole company cashflow break-even."

[1] Financials are preliminary and unaudited.

This announcement has been authorised for release by the Board.

For further information, please contact:
Dr Luke Reid
Chief Executive Officer
luke.reid@microba.com
https://ir.microba.com/welcome

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions. For more information visit www.microba.com.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
Microba Life Sciences Limited, and controlled entities	
ABN	**Quarter ended ("current quarter")**
82 617 096 652	30 June 2026

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	3,950	15,752
1.2	Payments for		
	(a) research and development	(283)	(1,018)
	(b) product manufacturing and operating costs	(1,832)	(8,435)
	(c) advertising and marketing	(761)	(2,029)
	(d) leased assets	-	(135)
	(e) staff costs	(3,500)	(14,984)
	(f) administration and corporate costs	(1,084)	(5,518)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	172	415
1.5	Interest and other costs of finance paid	(92)	(107)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	3,064
1.8	Other (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	**(3,430)**	**(12,995)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(135)	(235)
	(d) investments	-	-
	(e) intellectual property	(907)	(3,779)
	(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date $A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	16	94
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**(1,026)**	**(3,920)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	4,587	13,041
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(364)	(764)
3.5	Proceeds from borrowings	1,232	2,131
3.6	Repayment of borrowings	(49)	(652)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (Payment for principal portion of lease liabilities)	(248)	(682)
3.10	**Net cash from / (used in) financing activities**	**5,158**	**13,074**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	7,280	11,742
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(3,430)	(12,995)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(1,026)	(3,920)

Consolidated statement of cash flows		Current quarter $A'000	Year to date $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	5,158	13,074
4.5	Effect of movement in exchange rates on cash held	(33)	48
4.6	**Cash and cash equivalents at end of period**	**7,949**	**7,949**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	7,949	7,280
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**7,949**	**7,280**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	(114)
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: Payments included in item 6.1 above relate to Director Fees paid to Directors of Microba Life Sciences Limited during the period.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (Equipment & R&D Loan)	(2,694)	(2,694)
7.4	**Total financing facilities**	**(2,694)**	**(2,694)**

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

NovaSeqX Plus Funding Agreement: A funding arrangement was entered into with Westpac to refinance the purchase a state of the art Illumina NovaSeqX Plus DNA sequencing machine, the funding was secured against the machine. The previous funding arrangement was fully paid out on the 30 March 2026 and a new arrangement entered into with Westpac. The new loan amount of $629k was funded on the 30 March, which is repayable over 36 equal monthly instalments, with a fixed interest rate of 7.39%. The new NovaSeqX Plus funding is secured against the machine. The maturity date is 31 March 2029.

R&D Loan Advance Agreement: A $2.05m secured funding arrangement with Radium Capital was entered into whereby the Group's R&D tax refund for the FY26 income year has been advanced. The funding is secured against the Group's present and future right, title and interest in the R&D tax refund. The second tranche of advance was received during the quarter being $1,149k on 2 April 2026. The R&D Loan Advance is repayable upon receipt of the FY26 R&D tax refund, with a fixed interest rate of 16.00% per annum. The maturity date is 31 January 2027.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(3,430)
8.2	Cash and cash equivalents at quarter end (item 4.6)	7,949
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	**7,949**
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	**2.3**

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

N/A

8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?
N/A	

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: **16 July 2026**

Authorised by: **The Board of Directors**
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.